For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Tech firm adds ‘secret sauce’ to its breast density risk-crunching tool
+News
In print
Summer Hiatus
Tech firm adds ‘secret sauce’ to its breast density risk-crunching tool
Saturday 21 December 2019, 08:00 AM

Wellington-based Volpara Health Technologies uses an AI algorithm to assess breast density and inform clinicians about a woman’s tumour risk
We are on our summer break and the editorial office is closed until 13 January. We hope you enjoy this article which is part of Summer Hiatus, an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading
A small New Zealand health technology company says a service it provides is increasing the accuracy of mammography.
Wellington-based Volpara Hea
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.